Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide
- 14 September 2004
- journal article
- review article
- Published by Wolters Kluwer Health in Neurology
- Vol. 63 (5) , 901-903
- https://doi.org/10.1212/01.wnl.0000137050.43114.42
Abstract
The authors evaluated the efficacy of a combination of rituximab and temozolomide for recurrent or refractory primary CNS lymphoma (PCNSL). Fifteen patients with a median age of 69 years had a 53% objective response rate with acceptable toxicity. Median overall survival is 14 months and median progression free survival of responding patients is 7.7 months. This combination merits further study and provides a reasonable therapeutic alternative for older patients with progressive PCNSL.Keywords
This publication has 7 references indexed in Scilit:
- Treatment of CNS Lymphoma with the Anti-CD20 Antibody Rituximab: Experience with Two Cases and Review of the LiteratureOncology Research and Treatment, 2003
- Salvage treatment with etoposide (VP‐16), ifosfamide and cytarabine (Ara‐C) for patients with recurrent primary central nervous system lymphomaEuropean Journal of Haematology, 2003
- Rituximab Dose-Escalation Trial in Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2001
- Results of Intensive Chemotherapy Followed by Hematopoietic Stem-Cell Rescue in 22 Patients With Refractory or Recurrent Primary CNS Lymphoma or Intraocular LymphomaJournal of Clinical Oncology, 2001
- Treatment for Primary CNS Lymphoma: The Next StepJournal of Clinical Oncology, 2000
- PCV salvage chemotherapy for recurrent primary CNS lymphomaNeurology, 2000
- Intravenous Methotrexate as Initial Treatment for Primary Central Nervous System Lymphoma: Response to Therapy and Quality of Life of PatientsJournal of Neuro-Oncology, 1999